Welcome to the Kansas City Research Institute led by liver specialist Dr. Bradley Freilich. Dr. Freilich has over 20 years of clinical research experience in phase 1-4 trials, and has participated in over a hundred research trials.
In 2012 KCRI opened a 20 bed Clinical Research Unit (CRU) or phase I/IIa research center. While this facility is able to do studies with healthy volunteers, our specialty is in trials for patients with liver disease, including looking at any drug that needs to be tested in hepatic impaired patients.
Kansas City Research Institute conducts clinical trials yielding results that empower medical professionals, and patients to make informed health care decisions by advancing medical knowledge, promoting new and promising treatments, and facilitating access to otherwise unobtainable medications.
Gilead, Abbott/Abbvie, Johnson and Johnson, Vertex, Boehringer Ingelheim, Bristol Meyers Squibb, Salix, Merck, EMD Serono, Schering Plough, Astra Zynica, Roche, Idenex, Novartis, Valeant, Coley, Sanofi Aventis, Proctor and Gamble, Pharmasset, Inhibitex, SiClone, Glaxo Smith Kline, Anadys, La Jolla, Genentech, Amgen, Tibotec, Tekmira, Immuron